Neurotransmitters

Fundamentals of Synaptic Physiology

A synapse serves as the specialized functional junction where a sending, or presynaptic, neuron communicates with a receiving, or postsynaptic, target cell. This target cell may be another neuron, a muscle fiber, or a gland. Within this framework, neural integration occurs through summation processes. Spatial summation happens when multiple different presynaptic terminals fire simultaneously at various locations on the same neuron, thereby adding their individual excitatory inputs together to reach the necessary firing threshold. Conversely, temporal summation occurs when a single presynaptic terminal fires repeatedly in rapid succession, causing successive potentials to overlay and build upon one another before the previous charges can decay.

Synapses are categorized by their structural and functional properties. Structurally, synapses can be axodendritic, axosomatic, or axoaxonal. Functionally, they are divided into electrical and chemical synapses. While electrical synapses exist, the majority of synaptic transmissions in the human body are chemical. Neurotransmitters are the chemical messengers utilized by neurons to communicate across the synaptic cleft. When a nerve impulse arrives at the terminal bouton, voltage-gated $Ca^{2+}$ channels open, leading to an influx of $Ca^{2+}$ ions. This influx triggers synaptic vesicles to fuse with the cell membrane through the interaction of SNARE and SNAP proteins, discharging neurotransmitters into the synaptic cleft via exocytosis. These molecules then diffuse across the gap and bind to specific receptors on the postsynaptic membrane.

The binding of neurotransmitters to postsynaptic receptors leads to the opening or closing of ion channels, resulting in localized graded voltage changes. Excitatory Postsynaptic Potentials (EPSPs) are depolarizing and typically involve an influx of $Na^+$ or $Ca^{2+}$ ions, moving the membrane potential closer to the threshold. Inhibitory Postsynaptic Potentials (IPSPs) are hyperpolarizing, often involving an influx of $Cl^-$ or an efflux of $K^+$ ions, which stabilizes or moves the membrane potential further from the threshold. Transmission is eventually terminated through enzymatic degradation, active reuptake, or simple diffusion.

Classification and Molecular Diversity of Neurotransmitters

Neurotransmitters are classified into several distinct groups based on their molecular size and chemical structure. Small-molecule neurotransmitters include Acetylcholine (ACh), which is essential at the neuromuscular junction, autonomic ganglia, and postganglionic parasympathetic junctions. Another major group is the monoamines, which include catecholamines such as Dopamine, Epinephrine, and Norepinephrine, as well as serotonin. Amino acids constitute another vital category, with Glutamate serving as the primary excitatory transmitter in the brain and spinal cord, while GABA ($\text{γ-aminobutyric acid}$) and Glycine serve as the major inhibitory transmitters in the brain and spinal cord/brainstem, respectively.

Large-molecule neurotransmitters, known as neuropeptides, include substances like Substance P, poly-peptides, Vasopressin, Oxytocin, and various opioids such as Enkephalin and Endorphins. Unlike small-molecule transmitters that are typically synthesized in the axon terminals, neuropeptides are often synthesized in the cell body and transported to the terminal. Additionally, there are unconventional transmitters such as gaseous molecules like Nitric Oxide (NO) and Carbon Monoxide (CO). Nitric oxide is not stored in vesicles but is synthesized on demand from arginine by nitric oxide synthase and diffuses easily across membranes.

Endocannabinoids, such as $2\text{-arachidonyl glycerol}$ and anandamide, represent a class of lipid-based messengers. These are synthesized in response to $Ca^{2+}$ influx and are unique because they often travel backwards across the synaptic cleft. This retrograde signaling allows them to bind to presynaptic terminals and inhibit further transmitter release. Finally, purines and pyrimidines, such as Adenosine and UTP, also function within the signaling milieu of the nervous system.

Receptor Classification and Desensitization Dynamics

Postsynaptic receptors are broadly divided into ionotropic and metabotropic types. Ionotropic receptors are ligand-gated ion channels that open immediately upon neurotransmitter binding to allow the flow of ions. Examples include nicotinic ACh receptors, Glycine receptors, $GABA_A$ and $GABA_C$ receptors, the Serotonin $5\text{-HT}_3$ receptor, and Glutamate receptors such as NMDA, AMPA, and kainate. These receptors are often structural pentamers or tetramers, facilitating fast synaptic transmission.

Metabotropic receptors act through G-protein-coupled mechanisms (GPCRs) to activate second messengers. These receptors do not form an ion pore themselves; instead, they trigger intracellular signaling cascades that can change protein activity or gene expression within the neuron. All five dopamine receptors, adrenoceptors ($α$ and $β$), muscarinic ACh receptors, $GABA_B$ receptors, and most serotonin receptors (except $5\text{-HT}_3$) fall into this category. These produce slower, more long-lasting effects compared to ionotropic receptors.

Receptor downregulation and desensitization are critical mechanisms for maintaining homeostasis. Desensitization occurs when receptors remain on the membrane but undergo chemical modifications that make them less responsive to their ligands. This can be homologous, where the cell loses responsiveness only to the specific ligand present in excess, or heterologous, where the cell becomes broadly unresponsive to multiple different ligands. Prolonged exposure to chemical messengers can lead to receptor downregulation, effectively reducing the sensitivity of the neural circuit.

Mechanisms of Signal Termination and Neurotransmitter Removal

For a neural signal to remain discrete and meaningful, neurotransmitters must be rapidly removed from the synaptic cleft. There are four primary mechanisms for this removal. Enzymatic degradation is a major pathway, exemplified by Acetylcholinesterase (AChE). This enzyme hydrolyzes Acetylcholine into inactive acetate and choline. Many insecticides work by irreversibly inhibiting this enzyme, leading to toxic overstimulation. Neuropeptides are similarly broken down by extracellular peptidases into inactive amino acids.

Reuptake by the presynaptic neuron is another dominant mechanism, involving active transport pumps. Serotonin is cleared by the Serotonin Transporter (SERT), while Norepinephrine is cleared by the Norepinephrine Transporter (NET). These transporters are significant pharmacological targets; for instance, Selective Serotonin Reuptake Inhibitors (SSRIs) block SERT to treat depression. Once inside the cytoplasm, transmitters like catecholamines are either repackaged into vesicles or destroyed by intracellular enzymes like Monoamine Oxidase (MAO) and Catechol-O-methyltransferase (COMT).

Glial cell clearance involves astrocytes, which actively remove excess neurotransmitters like Glutamate from the synaptic cleft. In astrocytes, Glutamate is converted into Glutamine and then shuttled back into the neuron for recycling. Finally, simple diffusion allows some neurotransmitter molecules to drift away from the synaptic cleft into the surrounding extracellular fluid, where they can no longer activate the postsynaptic receptors.

Neuromodulation and Distributed Neural Systems

Neuromodulators differ from primary neurotransmitters in that they have little to no direct excitatory or inhibitory effect on their own. Instead, they function to fine-tune and adjust the overall sensitivity and activity of neural circuits. They act on a broader scale, adjusting physiological environments and altering response thresholds. For example, fluctuations in serotonin and norepinephrine can alter human taste thresholds based on conditions like depression or anxiety. Drugs like benzodiazepines and barbiturates act as neuromodulators at GABA synapses by potentiating GABA's inhibitory actions, increasing $Cl^-$ influx and inducing sedation.

The Central Nervous System (CNS) features several core neuromodulatory systems. The Noradrenergic system originates in the locus coeruleus and projects widely to modulate arousal and neural circuits. The Serotonergic system originates in the raphe nuclei and projects to the hypothalamus, limbic system, and neocortex. The Dopaminergic system, originating in the substantia nigra and ventral tegmental area (VTA), projects to the striatum and prefrontal cortex. Lastly, the Cholinergic system originates in the basal forebrain and pontomesencephalotegmental complex, projecting to the hippocampus and thalamus to regulate sleep-wake states and memory.

Acetylcholine: The Cholinergic System

Acetylcholine is a small-molecule transmitter utilized in both the CNS and the Peripheral Nervous System (PNS). In the PNS, it triggers skeletal muscle contraction at the neuromuscular junction, mediates signal transmission in all autonomic ganglia, and drives the parasympathetic "rest and digest" functions. In the CNS, cholinergic neurons are concentrated in the Basal Forebrain Complex and the Pontomesencephalic Cholinergic Complex, where they regulate sleep, learning, and memory. ACh is synthesized in the presynaptic cytoplasm from acetyl-CoA and choline by the enzyme Choline acetyltransferase (ChAT). Choline is taken up via a $Na^+$ dependent transporter, a step that can be blocked by the drug hemicholinium.

There are two main types of ACh receptors. Nicotinic receptors are fast-acting ionotropic channels. At the neuromuscular junction, they are known as $N_M$ receptors (blocked by curare), while in the CNS and ganglia, they are $N_N$ receptors (blocked by hexamethonium). Each nerve impulse at the neuromuscular junction triggers the release of ACh from approximately 60 vesicles, each containing about 10,000 molecules. Muscarinic receptors are slower-acting metabotropic GPCRs with five subtypes ($M_1$ to $M_5$). $M_2$ receptors in the heart decrease cAMP and open $K^+$ channels to slow the heart rate, while $M_3$ receptors in smooth muscles and glands increase intracellular $Ca^{2+}$ to stimulate secretion. All muscarinic receptors are characteristically blocked by the drug atropine.

Pathologically, Alzheimer's disease is characterized by a profound loss of cholinergic neurons originating in the nucleus basalis of Meynert, leading to cognitive decline. This is managed with acetylcholinesterase inhibitors like donepezil or galantamine, which delay symptoms for up to 12 months in about 50% of patients. Myasthenia gravis is an autoimmune disorder where antibodies destroy nicotinic receptors at the neuromuscular junction. This is treated with inhibitors like neostigmine to prolong the presence of ACh in the cleft. Conversely, toxic overstimulation of the cholinergic system by nerve gases or organophosphate pesticides causes miosis, profuse salivation, and convulsions.

Catecholamines: Norepinephrine and Epinephrine

Norepinephrine functions as both a neurotransmitter and a hormone. In the PNS, it is the primary transmitter for most sympathetic postganglionic nerves. In the CNS, it originates in the locus coeruleus and projects throughout the brain to modulate arousal. It binds to adrenergic receptors, having a higher affinity for $α$ than for $β$ receptors. The $α_1$ receptor is excitatory and mediates vasoconstriction via the IP3/DAG pathway, while $α_2$ receptors often act as presynaptic autoreceptors to inhibit further release. Stimulation of $β$ receptors in the heart increases heart rate (chronotropic effect) and contraction force (inotropic effect) by increasing cAMP levels.

Epinephrine is released mainly into the bloodstream by the adrenal medulla during the fight-or-flight response. It targets both $α$ and $β$ receptors. Specifically, $β_1$ stimulation increases cardiac output, while $β_2$ stimulation leads to vasodilation in skeletal muscles and bronchodilation in the lungs. Both norepinephrine and epinephrine are cleared via reuptake through NET and degraded by MAO and COMT. The primary urinary metabolite resulting from this degradation is vanillylmandelic acid (VMA), along with metanephrine.

Dopamine: Systems, Receptors, and Clinical Significance

Dopamine is a catecholamine synthesized from the amino acid tyrosine, where tyrosine is converted to DOPA by tyrosine hydroxylase (the rate-limiting step), then to dopamine by dopa decarboxylase. It acts exclusively through G-protein-coupled receptors. $D_1$-like receptors ($D_1$ and $D_5$) increase intracellular cAMP, while $D_2$-like receptors ($D_2$, $D_3$, and $D_4$) reduce it. Dopamine signals are terminated by reuptake via a $Na^+$ and $Cl^-$ dependent transporter and metabolized by MAO and COMT.

Clinically, dopamine is vital for motor control, psychiatric health, and endocrinology. Parkinson's disease results from the degeneration of dopaminergic neurons in the substantia nigra, leading to rigidity and bradykinesia; it is treated with L-dopa. Huntington's disease involves an excess of dopaminergic influence due to loss of inhibitory neurons, resulting in chorea. In psychiatry, overstimulation of $D_2$ receptors in the limbic system is linked to schizophrenia, while the stimulation of $D_3$ receptors in the nucleus accumbens drives addiction. Dopamine also acts as the primary prolactin-inhibiting hormone; thus, dopamine antagonists can cause hyperprolactinemia and galactorrhea. Furthermore, $D_2$ antagonists are used as anti-emetics because the area postrema (chemoreceptor trigger zone) is rich in these receptors.

Outside the CNS, dopamine exhibits dose-dependent cardiovascular effects. At low doses, it acts on peripheral dopaminergic receptors to produce renal vasodilation. At moderate doses, it stimulates cardiac $β_1$ receptors for a positive inotropic effect and triggers norepinephrine release. This makes intravenous dopamine a vital agent for treating traumatic and cardiogenic shock, as it raises systolic blood pressure without significantly elevating diastolic pressure.

Amino Acids, Serotonin, and Others

Serotonin ($5\text{-HT}$) is synthesized from tryptophan and is found in high concentrations in the GI tract, blood platelets, and the raphe nuclei. It regulates mood, sleep, and pain. Glutamate and Aspartate are the primary excitatory amino acids; Glutamate is responsible for approximately 75% of fast excitatory transmission in the CNS. Aspartate is closely related and gives the NMDA receptor its name. GABA is the major inhibitory transmitter in the brain, acting through fast ionotropic receptors ($GABA_A$) and slower metabotropic receptors ($GABA_B$).

Glycine serves a dual role; it is an inhibitory transmitter in the spinal cord and brainstem (increasing $Cl^-$ conductance) but also acts as an essential co-agonist at NMDA receptors to facilitate glutamate-mediated excitation. Large-molecule peptides like opioids (Endorphins, Enkephalins, Dynorphins) mediate analgesia, euphoria, and GI motility. Non-opioid peptides like Substance P are key mediators at the first synapse of pain transmission, while others like VIP and Neuropeptide Y regulate gut peristalsis and feeding behavior.

Neuroplasticity

Neuroplasticity is the ability of the nervous system to reorganize its structure and function in response to experience or injury. Synaptic plasticity involves short-term or long-term alterations in the strength of synaptic connections. Long-Term Potentiation (LTP) is a persistent enhancement of postsynaptic response following repeated stimulation, whereas Long-Term Depression (LTD) is a persistent decrease in synaptic strength. These processes are fundamental to learning and memory.

Structural or cortical neuroplasticity involves larger-scale remapping. Experience-driven remapping occurs when practicing new skills enlarges the corresponding motor or somatosensory brain regions. Cross-modal plasticity allows one sense to claim the cortical space of another, such as blind